A dual listing "MAY" offer increased exposure, however this...

A dual listing "MAY" offer increased exposure, however this biotech is unique, with nothing like it anywhere (at present). The IP they have with this, once it is all out there, will place OCC firmly in the sights of larger organisations that likely could exploit this far better in the US than OCC could on their own. It is this reason that I now have so much OCC exposure after various buys over the last couple of years.


From what I have seen with others doing this , the US process is onerous and takes considerable time, will OCC do it? I have no idea. For now, the OCC market cap is way too small, this I am certain will change.

One thing I would like to see is the relations between AUS and China improve. With exposure in China OCC will have a massive market exposure to a country plagued with tendon problems inherently. However the Asian market has this now generally so OCC will still obtain the benefits of this.

It would not surprise me to see OCC get a takeover offer, both sad to see biotech like this go overseas yet the offer would push the SP it the stratosphere (dare I say lol). But seriously a T/O would/should be a big premium on the current SP.So far this has been an interesting, beneficial journey for me.